ZATA is developing a nucleic acid platform technology that enables the self-delivery of oligotherapeutics that can be applied across a wide range of therapeutic areas with unmet medical needs such as cancer, infectious, and genetic diseases.
ZATA is also developing a novel class of antipathogen compounds that will enable pathogen free blood products intended for transfusion.
ZATA Pharmaceuticals, Inc. is a small start-up that was founded in 2008 and is structured as a privately held C-Corporation.
ZATA is based in Worcester, MA at the Massachusetts Biomedical Initiatives (MBI) facilities.
ZATA’s modern oligotherapeitcs will fully satisfy all complex criteria of optimal oligotherapy compounds.
ZATA’s antipathogen compounds are capable of inactivating existing and emerging blood borne infectious agents if presented in pre-transfusion blood products.